» Articles » PMID: 34169495

The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper

Abstract

Background: One year after the declaration of the coronavirus disease 2019 (COVID-19) pandemic by the World Health Organization (WHO) and despite the implementation of mandatory physical barriers and social distancing, humanity remains challenged by a long-lasting and devastating public health crisis.

Management: Non-pharmacological interventions (NPIs) are efficient mitigation strategies. The success of these NPIs is dependent on the approval and commitment of the population. The launch of a mass vaccination program in many countries in late December 2020 with mRNA vaccines, adenovirus-based vaccines, and inactivated virus vaccines has generated hope for the end of the pandemic.

Current Issues: The continuous appearance of new pathogenic viral strains and the ability of vaccines to prevent infection and transmission raise important concerns as we try to achieve community immunity against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) and its variants. The need of a second and even third generation of vaccines has already been acknowledged by the WHO and governments.

Perspectives: There is a critical and urgent need for a balanced and integrated strategy for the management of the COVID-19 outbreaks organized on three axes: (1) revention of the SARS-CoV-2 infection, (2) and early diagnosis of patients at risk of disease worsening, and (3) of medical care (PDA).

Conclusion: The "PDA strategy" integrated into state policy for the support and expansion of health systems and introduction of digital organizations (i.e., telemedicine, e-Health, artificial intelligence, and machine-learning technology) is of major importance for the preservation of citizens' health and life world-wide.

Citing Articles

An Application of : A Spiritual, Cost-Effective, Indigenous Low-Intensity Psychological Intervention to Manage Common Mental Disorders: A Cross-Sectional Pilot Study in India.

Balkrishna A, Gupta A, Ghosh S, Arya V J Evid Based Integr Med. 2024; 29:2515690X241284280.

PMID: 39403733 PMC: 11526240. DOI: 10.1177/2515690X241284280.


Sex-based differences in risk of ischaemic stroke or systemic embolism after BNT162b2 or CoronaVac COVID-19 vaccination in patients with atrial fibrillation: a self-controlled case series and nested case-control study.

Ye X, Huang C, Yan V, Kang W, Fan M, Tsang G Eur Heart J Cardiovasc Pharmacother. 2023; 9(5):403-412.

PMID: 36918200 PMC: 10385083. DOI: 10.1093/ehjcvp/pvad015.


STIMULATE-ICP-Delphi (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways Delphi): Study protocol.

van der Feltz-Cornelis C, Sweetman J, Allsopp G, Attree E, Crooks M, Cuthbertson D PLoS One. 2022; 17(11):e0277936.

PMID: 36449461 PMC: 9710789. DOI: 10.1371/journal.pone.0277936.


A Qualitative Evaluation of COVID-19 Preventative Response Activities in South Kivu, Democratic Republic of the Congo.

Aubourg M, Bisimwa L, Bisimwa J, Sanvura P, Williams C, Boroto R Int J Environ Res Public Health. 2022; 19(20).

PMID: 36294005 PMC: 9603344. DOI: 10.3390/ijerph192013424.


Isolation of Functional SARS-CoV-2 Antigen-Specific T-Cells with Specific Viral Cytotoxic Activity for Adoptive Therapy of COVID-19.

Garcia-Rios E, Leivas A, Mancebo F, Sanchez-Vega L, Lanzarot D, Aguado J Biomedicines. 2022; 10(3).

PMID: 35327433 PMC: 8944951. DOI: 10.3390/biomedicines10030630.


References
1.
Patell R, Chiasakul T, Bauer E, Zwicker J . Pharmacologic Thromboprophylaxis and Thrombosis in Hospitalized Patients with COVID-19: A Pooled Analysis. Thromb Haemost. 2020; 121(1):76-85. PMC: 7869062. DOI: 10.1055/s-0040-1721664. View

2.
Elalamy I, Gerotziafas G, Alamowitch S, Laroche J, Van Dreden P, Ageno W . SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia. Thromb Haemost. 2021; 121(8):982-991. PMC: 8322589. DOI: 10.1055/a-1499-0119. View

3.
Hacisuleyman E, Hale C, Saito Y, Blachere N, Bergh M, Conlon E . Vaccine Breakthrough Infections with SARS-CoV-2 Variants. N Engl J Med. 2021; 384(23):2212-2218. PMC: 8117968. DOI: 10.1056/NEJMoa2105000. View

4.
Bilal , Bashir M, Benghoul M, Numan U, Shakoor A, Komal B . Environmental pollution and COVID-19 outbreak: insights from Germany. Air Qual Atmos Health. 2020; 13(11):1385-1394. PMC: 7396458. DOI: 10.1007/s11869-020-00893-9. View

5.
Ribas A, Sengupta R, Locke T, Zaidi S, Campbell K, Carethers J . Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited. Cancer Discov. 2020; 11(2):233-236. PMC: 8053003. DOI: 10.1158/2159-8290.CD-20-1817. View